How Do Viral and Host Factors Modulate the Sexual Transmission of HIV? Can Transmission Be Blocked?

Overview

Journal PLoS Med

Specialty General Medicine

Date 2006 Feb 24

PMID 16492075

Citations 20

Authors

Kalpana Gupta

Per Johan Klasse

Affiliations

Soon will be listed here.

Citing Articles

Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.

Klasse P, Moore J J Virol. 2022; 96(8):e0003422.

PMID: 35384694 PMC: 9044961. DOI: 10.1128/jvi.00034-22.

The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.

Harris J Health Policy Technol. 2022; 11(2):100619.

PMID: 35340773 PMC: 8935961. DOI: 10.1016/j.hlpt.2022.100619.

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Pyles R, Baum M Open Virol J. 2018; 12:1-13.

PMID: 29541273 PMC: 5842390. DOI: 10.2174/1874357901812010001.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles R PLoS One. 2017; 12(9):e0184303.

PMID: 28880948 PMC: 5589224. DOI: 10.1371/journal.pone.0184303.

The regulation of inflammatory pathways and infectious disease of the cervix by seminal fluid.

Adefuye A, Katz A, Sales K Patholog Res Int. 2014; 2014:748740.

PMID: 25180120 PMC: 4144323. DOI: 10.1155/2014/748740.

References

Khanna K, Whaley K, Zeitlin L, Moench T, Mehrazar K, Cone R . Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest. 2002; 109(2):205-11. PMC: 150835. DOI: 10.1172/JCI13236. View

Veazey R, Springer M, Marx P, Dufour J, Klasse P, Moore J . Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med. 2005; 11(12):1293-4. DOI: 10.1038/nm1321. View

Mascola J . Defining the protective antibody response for HIV-1. Curr Mol Med. 2003; 3(3):209-16. DOI: 10.2174/1566524033479799. View

Kozlowski P, Neutra M . The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med. 2003; 3(3):217-28. DOI: 10.2174/1566524033479852. View

Pope M, Haase A . Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003; 9(7):847-52. DOI: 10.1038/nm0703-847. View

Moore J, Kitchen S, Pugach P, Zack J . The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004; 20(1):111-26. DOI: 10.1089/088922204322749567. View

Galvin S, Cohen M . The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2(1):33-42. DOI: 10.1038/nrmicro794. View

Shattock R, Moore J . Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol. 2004; 1(1):25-34. DOI: 10.1038/nrmicro729. View

Derdeyn C, Decker J, Bibollet-Ruche F, Mokili J, Muldoon M, Denham S . Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004; 303(5666):2019-22. DOI: 10.1126/science.1093137. View

10.

Koning F, Jansen C, Dekker J, Kaslow R, Dukers N, van Baarle D . Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS. 2004; 18(8):1117-26. DOI: 10.1097/00002030-200405210-00005. View

11.

Veazey R, Lackner A . Getting to the guts of HIV pathogenesis. J Exp Med. 2004; 200(6):697-700. PMC: 2211972. DOI: 10.1084/jem.20041464. View

12.

Ganesh L, Leung K, Lore K, Levin R, Panet A, Schwartz O . Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol. 2004; 78(21):11980-7. PMC: 523246. DOI: 10.1128/JVI.78.21.11980-11987.2004. View

13.

Tsai C, Emau P, Follis K, Beck T, Benveniste R, Bischofberger N . Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998; 72(5):4265-73. PMC: 109656. DOI: 10.1128/JVI.72.5.4265-4273.1998. View

14.

J Wawer M, H Gray R, Sewankambo N, Serwadda D, Li X, Laeyendecker O . Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005; 191(9):1403-9. DOI: 10.1086/429411. View

15.

Mestecky J, Moldoveanu Z, Russell M . Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005; 53(5):208-14. DOI: 10.1111/j.1600-0897.2005.00267.x. View

16.

Frost S, Liu Y, Kosakovsky Pond S, Chappey C, Wrin T, Petropoulos C . Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol. 2005; 79(10):6523-7. PMC: 1091710. DOI: 10.1128/JVI.79.10.6523-6527.2005. View

17.

Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B . Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005; 79(10):6528-31. PMC: 1091724. DOI: 10.1128/JVI.79.10.6528-6531.2005. View

18.

Villa L, Costa R, Petta C, Andrade R, Ault K, Giuliano A . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5):271-8. DOI: 10.1016/S1470-2045(05)70101-7. View

19.

Miller C, Li Q, Abel K, Kim E, Ma Z, Wietgrefe S . Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005; 79(14):9217-27. PMC: 1168785. DOI: 10.1128/JVI.79.14.9217-9227.2005. View

20.

Maher D, Wu X, Schacker T, Horbul J, Southern P . HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A. 2005; 102(32):11504-9. PMC: 1183539. DOI: 10.1073/pnas.0500848102. View